VBIV
$1.74
Vbi Vaccines Inc CS
($.09)
(4.92%)
VBIV
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.07)
Revenue:  $1.04 Mil
Tuesday
Mar 1
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VBIV reports earnings?
Beat
Meet
Miss

Where is VBIV's stock price going from here?
Up
Flat
Down
Stock chart of VBIV
Analysts
Summary of analysts' recommendations for VBIV
Score
Grade
Pivots
Resistance
$1.96
$1.91
$1.83

$1.78

Support
$1.70
$1.65
$1.57
Tweet
Growth
Description
VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA.